Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Authors not listed

First Affiliated Hospital of Wenzhou Medical University · 2022

Abstract

This is a prospective, single-center, open-label clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) versus rituximab combined with CHOP or CDOP (R-CHOP or R-CDOP) in elderly patients with diffuse large B cell lymphoma treated for the first time.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2022). The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. <em>First Affiliated Hospital of Wenzhou Medical University</em>. https://clinicaltrials.gov/study/NCT05428670
Vancouver
Anonymous. The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. First Affiliated Hospital of Wenzhou Medical University. 2022.
BibTeX
@misc{anon2022TheEff, title = {The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.}, author = {Anonymous}, journal = {First Affiliated Hospital of Wenzhou Medical University}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings